BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
Фаза 3
Завершено
NCT03762018
| Заболевание | Pleural Mesothelioma Malignant Advanced |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | ETOP IBCSG Partners Foundation |
|---|
| Статус | Завершено |
|---|
| Участники | 400 участн. |
|---|
| Вмешательство | Carboplatin, Pemetrexed, Bevacizumab, Atezolizumab |
|---|
| Дата начала | 30.04.2019 |
|---|
| Дата завершения | 1.09.2023 |
|---|
| Публикация результатов | 14.05.2026 |
|---|
Кратко
The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesothelioma. The efficacy (whether the treatment works), safety and tolerability (side effects of treatment) of atezolizumab plus bevacizumab in combination with standard chemotherapy versus bevacizumab in combination with standard chemotherapy will be investigated.
Overall Survival (OS)
From randomization until death from any cause, up to 52 months. · months
| Atezolizumab Plus Bevacizumab Plus Chemotherapy | 20.5 months |
|---|
| Bevacizumab Plus Chemotherapy | 18.1 months |
|---|
| p-value | 0.14 |
|---|
| Hazard Ratio (HR) | 0.84 (95% CI 0.66–1.06) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.